CTOs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Sunovion Pharmaceuticals

Sunovion Pharmaceuticals Inc. leads the way to a healthier tomorrow by creating medicines for respiratory diseases and central nervous system disorders.

Wockhardt USA

Wockhardt USA is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RTI Surgical®

RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tis...

Integrated Project Services

IPS-Integrated Project Services, LLC is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations.

Alvogen

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.